Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2

@article{Torre2010RecomendacionesPE,
  title={Recomendaciones para el tratamiento farmacol{\'o}gico de la hiperglucemia en la diabetes tipo 2},
  author={Edelmiro Men{\'e}ndez Torre and Francisco Javier Tejedor Tejedor and Sara Artola Men{\'e}ndez and Jes{\'u}s Mill{\'a}n N{\'u}{\~n}ez-Cort{\'e}s and {\'A}ngeles Alonso Garc{\'i}a and Manuel Puig Domingo and Jos{\'e} Ram{\'o}n Garc{\'i}a Sol{\'a}ns and Fernando {\'a}lvarez Guisasola and Javier Garc{\'i}a Alegr{\'i}a and Jos{\'e} Javier Mediavilla Bravo and Carlos Miranda Fern{\'a}ndez-Santos and Ram{\'o}n Romero Gonz{\'a}lez},
  journal={Avances en Diabetolog{\'i}a},
  year={2010},
  volume={26},
  pages={331-338}
}
35 Citations
...
1
2
3
4
...

References

SHOWING 1-10 OF 100 REFERENCES
Defining the Role of Repaglinide in the Management of Type 2 Diabetes Mellitus
  • O. Johansen, K. Birkeland
  • Medicine, Biology
    American journal of cardiovascular drugs : drugs, devices, and other interventions
  • 2007
TLDR
Repaglinide is a compound that can be used in both mono- and combination therapy for the treatment of both fasting and postprandial hyperglycemia in patients with T2DM and is associated with less weight gain than sulphonylureas and the glitazones.
Alpha-glucosidase inhibitors for type 2 diabetes mellitus.
TLDR
It remains unclear whether alpha-glucosidase inhibitors influence mortality or morbidity in patients with type 2 diabetes, and it is found that they have a significant effect on glycemic control and insulin levels, but no clinically relevant effects on lipids or body weight.
Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.
  • H. Rodbard, P. Jellinger, S. Schwartz
  • Medicine
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • 2009
TLDR
An algorithm to assist primary care physicians, endocrinologists, and others in the management of adult, nonpregnant patients with type 2 diabetes mellitus to achieve a hemoglobin A1c of 6.5% or less is presented, with recognition of the need for individualization to minimize the risks of hypoglycemia.
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.
TLDR
Adjunctive exenatide treatment for > or = 3 years in T2DM patients resulted in sustained improvements in glycemic control, cardiovascular risk factors, and hepatic biomarkers, coupled with progressive weight reduction.
Effect of pioglitazone on metabolic syndrome risk factors: results of double-blind, multicenter, randomized clinical trials*
TLDR
Treatment with pioglitazone as monotherapy or combination therapy led to sustained, positive effects on important components of metabolic syndrome in patients with type 2 diabetes, independent of effects on blood glucose control and, as such, could be translated to potential for reducing the risk of cardiovascular disease.
Meglitinide analogues for type 2 diabetes mellitus.
TLDR
There is no evidence available to indicate what effect meglitinides will have on important long-term outcomes, particularly mortality, butMeglitinides may offer an alternative oral hypoglycaemic agent of similar potency to metformin, and may be indicated where side effects of met formin are intolerable or where metform in is contraindicated.
Safety of Type 2 Diabetes Treatment With Repaglinide Compared With Glibenclamide in Elderly People
TLDR
The present study assessed the safety of repaglinide versus glibenclamide in elderly patients with type 2 diabetes, in terms of hypoglycemia and adverse events.
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes
TLDR
The CDA's process of data review with a “standardized evidence-based approach” and the participation of “over 90 authors and a steering committee of 18” concludes that the process removed “as much bias as possible,” implying that this approach was superior to the ADA/EASD consensus algorithm process.
Effect of a multifactorial intervention on mortality in type 2 diabetes.
TLDR
In at-risk patients with type 2 diabetes, intensive intervention with multiple drug combinations and behavior modification had sustained beneficial effects with respect to vascular complications and on rates of death from any cause and from cardiovascular causes.
...
1
2
3
4
5
...